Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma

Hong In Yoon, Jinsil Seong

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits. Among advanced diseases, liver-confined HCC, which invades the vasculature without extrahepatic metastasis, requires novel therapeutic management beyond using sorafenib alone. Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases. For advanced liver-confined HCC, focal liver irradiation, RT technological development, and optimal selection of RT-suitable patients enable clinicians to use RT-involving multimodality treatments based on oncologic principles, such as concurrent chemoradiotherapy, which represent effective multimodality treatments for several types of malignancy. Summary: In this review, we discuss the need to develop novel therapeutic approaches for liver-confined HCC and clinical applications of RT-involving multimodality treatments for advanced liver-confined HCC. Conclusion: RT-involving multimodality treatments can enhance the overall therapeutic successes for advanced liver-confined HCC and also provide potential cures to some patients via conversion to a resectable condition.

Original languageEnglish
Pages (from-to)90-98
Number of pages9
JournalOncology (Switzerland)
Volume87
DOIs
Publication statusPublished - 2014 Apr 20

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Liver
Therapeutics
Chemoradiotherapy
Liver Neoplasms
Liver Diseases
Neoplasms
Guidelines
Neoplasm Metastasis
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{fcde0a38b0c2466b937ff9a35907ec61,
title = "Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma",
abstract = "Background: Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits. Among advanced diseases, liver-confined HCC, which invades the vasculature without extrahepatic metastasis, requires novel therapeutic management beyond using sorafenib alone. Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases. For advanced liver-confined HCC, focal liver irradiation, RT technological development, and optimal selection of RT-suitable patients enable clinicians to use RT-involving multimodality treatments based on oncologic principles, such as concurrent chemoradiotherapy, which represent effective multimodality treatments for several types of malignancy. Summary: In this review, we discuss the need to develop novel therapeutic approaches for liver-confined HCC and clinical applications of RT-involving multimodality treatments for advanced liver-confined HCC. Conclusion: RT-involving multimodality treatments can enhance the overall therapeutic successes for advanced liver-confined HCC and also provide potential cures to some patients via conversion to a resectable condition.",
author = "Yoon, {Hong In} and Jinsil Seong",
year = "2014",
month = "4",
day = "20",
doi = "10.1159/000368151",
language = "English",
volume = "87",
pages = "90--98",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",

}

Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma. / Yoon, Hong In; Seong, Jinsil.

In: Oncology (Switzerland), Vol. 87, 20.04.2014, p. 90-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma

AU - Yoon, Hong In

AU - Seong, Jinsil

PY - 2014/4/20

Y1 - 2014/4/20

N2 - Background: Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits. Among advanced diseases, liver-confined HCC, which invades the vasculature without extrahepatic metastasis, requires novel therapeutic management beyond using sorafenib alone. Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases. For advanced liver-confined HCC, focal liver irradiation, RT technological development, and optimal selection of RT-suitable patients enable clinicians to use RT-involving multimodality treatments based on oncologic principles, such as concurrent chemoradiotherapy, which represent effective multimodality treatments for several types of malignancy. Summary: In this review, we discuss the need to develop novel therapeutic approaches for liver-confined HCC and clinical applications of RT-involving multimodality treatments for advanced liver-confined HCC. Conclusion: RT-involving multimodality treatments can enhance the overall therapeutic successes for advanced liver-confined HCC and also provide potential cures to some patients via conversion to a resectable condition.

AB - Background: Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits. Among advanced diseases, liver-confined HCC, which invades the vasculature without extrahepatic metastasis, requires novel therapeutic management beyond using sorafenib alone. Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases. For advanced liver-confined HCC, focal liver irradiation, RT technological development, and optimal selection of RT-suitable patients enable clinicians to use RT-involving multimodality treatments based on oncologic principles, such as concurrent chemoradiotherapy, which represent effective multimodality treatments for several types of malignancy. Summary: In this review, we discuss the need to develop novel therapeutic approaches for liver-confined HCC and clinical applications of RT-involving multimodality treatments for advanced liver-confined HCC. Conclusion: RT-involving multimodality treatments can enhance the overall therapeutic successes for advanced liver-confined HCC and also provide potential cures to some patients via conversion to a resectable condition.

UR - http://www.scopus.com/inward/record.url?scp=84922481099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922481099&partnerID=8YFLogxK

U2 - 10.1159/000368151

DO - 10.1159/000368151

M3 - Article

C2 - 25427739

AN - SCOPUS:84922481099

VL - 87

SP - 90

EP - 98

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -